Suppr超能文献

“非典型”多药耐药人类白血病细胞的药理学、分子学及细胞遗传学分析

Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.

作者信息

Beck W T, Cirtain M C, Danks M K, Felsted R L, Safa A R, Wolverton J S, Suttle D P, Trent J M

机构信息

Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.

出版信息

Cancer Res. 1987 Oct 15;47(20):5455-60.

PMID:2888532
Abstract

We previously described the cross-resistance patterns and cellular pharmacology of a human leukemic cell line, CEM/VM-1, selected for resistance to the epipodophyllotoxin teniposide (M. K. Danks et al., Cancer Res., 47: 1297-1301, 1987). Compared to CEM/VLB100, which is a well characterized "classic" multidrug-resistant (MDR) cell line, the CEM/VM-1 cells display "atypical" multidrug resistance (at-MDR) in that they are cross-resistant to a wide variety of natural product antitumor drugs, except the Vinca alkaloids, and they are not impaired in their ability to accumulate radiolabeled epipodophyllotoxin. We have extended our characterization of this at-MDR cell line in the present study. In comparison to CEM/VLB100 cells, we found that CEM/VM-1 cells are not cross-resistant to either actinomycin D or colchicine. Verapamil and chloroquine, which enhance the cytotoxicity of vinblastine in CEM/VLB100 cells, had little or no ability to do so in the CEM/VM-1 cells. Membrane vesicles of the two resistant sublines were examined for overexpression of the MDR-associated plasma membrane protein (P-glycoprotein, Mr 170,000 protein, or 180,000 glycoprotein) by photoaffinity labeling with the vinblastine analogue N-(p-azido[3-125I]salicyl)-N'-beta-aminoethylvindesine. We were unable to visualize the MDR-associated protein in the CEM/VM-1 membranes with this photoaffinity probe under conditions in which the P-glycoprotein was readily seen in the membranes of CEM/VLB100 cells. Furthermore, no hybridization of the pMDR1 complementary DNA was seen in slot-blot analyses of the RNA from at-MDR cells, indicating that the mdr gene coding for P-glycoprotein is not overexpressed as is the case in the classic MDR cells. However, cytogenetic analysis indicated that the CEM/VM-1 cells contained an abnormally banded region on chromosome 13q, suggesting that a gene other than mdr may be amplified in these cells. Thus, despite the two cell lines having approximately equal degrees of resistance to epipodophyllotoxins, our data indicate that the mechanism(s) responsible for at-MDR is different from that for classic, P-glycoprotein-associated MDR.

摘要

我们之前描述了一种人白血病细胞系CEM/VM-1的交叉耐药模式和细胞药理学特性,该细胞系是通过对表鬼臼毒素替尼泊苷产生耐药性筛选出来的(M.K.丹克斯等人,《癌症研究》,47: 1297 - 1301, 1987)。与特征明确的“经典”多药耐药(MDR)细胞系CEM/VLB100相比,CEM/VM-1细胞表现出“非典型”多药耐药(at-MDR),因为它们对多种天然产物抗肿瘤药物具有交叉耐药性,但对长春花生物碱除外,并且它们积累放射性标记表鬼臼毒素的能力未受损。在本研究中,我们扩展了对这种at-MDR细胞系的特性描述。与CEM/VLB100细胞相比,我们发现CEM/VM-1细胞对放线菌素D或秋水仙碱均无交叉耐药性。维拉帕米和氯喹可增强长春花碱对CEM/VLB100细胞的细胞毒性,但对CEM/VM-1细胞几乎没有或完全没有这种作用。通过用长春花碱类似物N-(对叠氮[3-125I]水杨基)-N'-β-氨基乙基长春花碱进行光亲和标记,检测了两个耐药亚系的膜囊泡中多药耐药相关质膜蛋白(P-糖蛋白,分子量170,000的蛋白或分子量180,000的糖蛋白)的过表达情况。在能轻易在CEM/VLB100细胞膜中看到P-糖蛋白的条件下,我们无法用这种光亲和探针在CEM/VM-1细胞膜中检测到多药耐药相关蛋白。此外,在对at-MDR细胞RNA的狭缝印迹分析中未见到pMDR1互补DNA的杂交信号,这表明编码P-糖蛋白的mdr基因不像在经典MDR细胞中那样过表达。然而,细胞遗传学分析表明,CEM/VM-1细胞在13q染色体上有一个异常带区,提示这些细胞中可能有mdr以外的基因被扩增。因此,尽管这两种细胞系对表鬼臼毒素的耐药程度大致相同,但我们的数据表明,导致at-MDR的机制与经典的、与P-糖蛋白相关的MDR机制不同。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验